CN115487340B - 一种负载活性氧的细菌纤维素敷料及其制备方法 - Google Patents
一种负载活性氧的细菌纤维素敷料及其制备方法 Download PDFInfo
- Publication number
- CN115487340B CN115487340B CN202211349098.2A CN202211349098A CN115487340B CN 115487340 B CN115487340 B CN 115487340B CN 202211349098 A CN202211349098 A CN 202211349098A CN 115487340 B CN115487340 B CN 115487340B
- Authority
- CN
- China
- Prior art keywords
- hydrogen peroxide
- bacterial cellulose
- dressing
- solution
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920002749 Bacterial cellulose Polymers 0.000 title claims abstract description 36
- 239000005016 bacterial cellulose Substances 0.000 title claims abstract description 36
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 239000001301 oxygen Substances 0.000 title claims abstract description 12
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 238000006213 oxygenation reaction Methods 0.000 title description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 102
- 239000000243 solution Substances 0.000 claims abstract description 26
- 239000012528 membrane Substances 0.000 claims abstract description 25
- 230000001954 sterilising effect Effects 0.000 claims abstract description 11
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 9
- 238000005520 cutting process Methods 0.000 claims abstract description 4
- 238000004806 packaging method and process Methods 0.000 claims abstract description 4
- 239000003929 acidic solution Substances 0.000 claims abstract description 3
- 239000012670 alkaline solution Substances 0.000 claims abstract description 3
- 230000002829 reductive effect Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 9
- -1 nipagin ester Chemical class 0.000 claims description 9
- 235000002906 tartaric acid Nutrition 0.000 claims description 9
- 239000011975 tartaric acid Substances 0.000 claims description 9
- 229920002413 Polyhexanide Polymers 0.000 claims description 8
- 239000000645 desinfectant Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 6
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 5
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 5
- 235000002837 Acetobacter xylinum Nutrition 0.000 claims description 4
- 241001136169 Komagataeibacter xylinus Species 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 239000005708 Sodium hypochlorite Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 235000006408 oxalic acid Nutrition 0.000 claims description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 3
- 230000003068 static effect Effects 0.000 claims description 3
- 206010027146 Melanoderma Diseases 0.000 claims description 2
- 238000010306 acid treatment Methods 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 2
- 238000000354 decomposition reaction Methods 0.000 abstract description 16
- 206010052428 Wound Diseases 0.000 abstract description 13
- 208000027418 Wounds and injury Diseases 0.000 abstract description 13
- 230000029663 wound healing Effects 0.000 abstract description 5
- 239000003242 anti bacterial agent Substances 0.000 abstract description 3
- 206010048038 Wound infection Diseases 0.000 abstract 1
- 239000003223 protective agent Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 description 17
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 239000003899 bactericide agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 4
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- KCQUJORJVXQRST-UHFFFAOYSA-N acetic acid;ethane-1,2-diamine Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NCCN KCQUJORJVXQRST-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000007524 organic acids Chemical group 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- FRTNIYVUDIHXPG-UHFFFAOYSA-N acetic acid;ethane-1,2-diamine Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NCCN FRTNIYVUDIHXPG-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- VOULLQDGKZXPMY-UHFFFAOYSA-N carbonic acid hydrogen peroxide Chemical compound OO.OC(O)=O VOULLQDGKZXPMY-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005536 corrosion prevention Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/11—Peroxy compounds, peroxides, e.g. hydrogen peroxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/206—Biguanides, e.g. chlorohexidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种负载活性氧的细菌纤维素敷料及其制备方法,分别使用酸性溶液和碱性溶液处理细菌纤维素膜,漂洗;然后浸入包含过氧化氢、过氧化氢保护剂和抗菌剂的活性溶液中,取出、分切包装。本发明制备获得的细菌纤维素敷料为湿性敷料产品,不仅可以轻松的贴敷于创面,而且贴敷料于创面可长达7天。即使在高温、辐照灭菌下,过氧化氢分解速率大大下降,使得敷料可持续输送ROS,降低创面感染,促进创面愈合。
Description
技术领域
本发明涉及医用敷料领域,具体地说涉及细菌纤维素敷料,特别涉及一种负载活性氧的细菌纤维素敷料及其制备方法。
背景技术
过氧化氢作为一种活性氧(Reactive oxygen species,ROS)起着十分重要的作用,其作为不依赖转录的可扩散损伤信号,可以调节依赖转录的细胞反应。活性氧家族的成员包括超氧阴离子·O2–,过氧化物O2 2-,过氧化氢H2O2。
复杂的伤口愈合过程需要大量的能量。如果伤口感染,则存在甚至更大的能量需求,这又意味着对氧的需求更大。氧涉及自然愈合过程的许多机制。其在代谢支持、基质修复、抗菌/感染控制以及信号传导和细胞反应的控制中具有关键作用。与没有足够氧合的那些伤口相比,接受足够氧的伤口通常愈合速度更快。缺血/缺氧可以直接抑制伤口愈合过程,诸如血管生成、胶原合成和上皮形成,并且还阻碍白细胞杀死细菌的能力。随着细菌繁殖,更多的白细胞迁移到伤口部位,进一步增加氧消耗。
新血管的形成是创面愈合所必需的条件。当产生伤口时,身体的自然防御被激活。中性粒细胞在创伤后不久聚集在创伤部位,释放杀菌活性氧(ROS)和过氧化氢(H2O2)以杀死细菌并预防感染。而新生血管的形成必须由适当的信号触发。在高氧环境中,巨噬细胞和白细胞可触发该信号。巨噬细胞响应于环境刺激到达伤口,吞噬外来颗粒,并释放血管内皮生长因子(VEGF),VEGF是一种血管生成因子,对伤口愈合至关重要。从而引发坏死组织降解,新的胶原形成和组织内皮细胞迀移/定殖。
现阶段负载ROS的敷料产品较少,已上市应用的产品主要有以蜂蜜为主要原料的膏剂,在文献中报道的主要以凝胶剂型为主。膏剂和凝胶剂型存在难以均匀涂抹、容易变干,在创面中组织酶的作用下,凝胶降解吸收较快,无法持续输送ROS的缺陷。
发明内容
发明目的:本发明的目的是提供一种负载活性氧以提高抗菌效果且不易导致活性氧分解的细菌纤维素敷料的制备方法,本发明还有一个目的是提供前述方法制备获得的细菌纤维素敷料产品。
技术方案:为了实现上述发明目的,本发明的一种负载活性氧的细菌纤维素敷料制备方法,包括如下步骤:分别使用酸性溶液和碱性溶液处理细菌纤维素膜,漂洗;然后浸入活性溶液中,取出、分切包装;
其中,所述活性溶液包括过氧化氢、至少一种抗菌剂、以及至少一种过氧化氢稳定剂;所述过氧化氢稳定剂选自乙二胺四乙酸二钠、乙二胺四乙酸、乙二胺五乙酸、磷酸钠、三聚磷酸钠、酒石酸、苹果酸、葡糖酸的任意一种或多种的组合。
作为本发明的优选方案,所述过氧化氢稳定剂可选择地选自乙二胺四乙酸二钠、乙二胺四乙酸、乙二胺五乙酸的任意一种,最优选用乙二胺四乙酸二钠。乙二胺四乙酸二钠为白色粉末,易溶于水。因能与微生物生长所需的微量元素如镁等络合,具有协同防腐杀菌的作用。在与其他防腐杀菌剂联合使用时能起到协同增效的作用,特别是与山梨酸钾、尼泊金酯、PHMB等联合使用时能够提高杀菌作用,同时能降低防腐杀菌剂的用量。该类稳定剂主要针对细菌纤维素膜中存在的金属离子导致过氧化氢分解。
除此之外,本发明还可选择地提供一类羟基羧酸类过氧化氢稳定剂,含有羟基、羧基配位基团,在水中可以与金属离子形成不溶的螯合物,例如酒石酸、苹果酸、葡糖酸,其中优选酒石酸。羟基羧酸类稳定剂为有机酸类物质,利用羟基羧酸类稳定剂更有利于提供弱酸性的敷料产品,在临床上更有利于抑制细菌生长、控制感染,同时具备促进慢性创面愈合的效果。
除此之外,本发明还可选择地提供一类磷酸盐型过氧化氢稳定剂,值得注意的是,这一类稳定剂含有磷酸配位基团,在水中可与金属离子产生凝胶状沉淀,在特定场合上使用具有出色的效果。
进一步地,所述活性溶液中过氧化氢的浓度为0.01-1wt%,优选的浓度为0.05-0.5wt%;所述过氧化氢稳定剂的浓度为0.001-0.5wt%,优选的浓度为0.01-0.1wt%。
进一步地,所述抗菌剂选自单胍类消毒剂、双胍类消毒剂、尼泊金酯类消毒剂、葡萄糖酸氯己定的任意一种或多种的组合。所述抗菌剂浓度为0.0001-0.1%。
其中,所述尼泊金酯类消毒剂选自包括但不限于尼泊金甲酯、尼泊金乙酯、尼泊金丙酯的任意一种或多种的组合,优选浓度范围为0.01-0.4%;所述葡萄糖酸氯己定,优选浓度范围为0.01-1%。单胍或双胍类消毒剂的优选浓度范围为0.0001-0.1%。
进一步地,所述细菌纤维素膜为利用木醋杆菌经静态培养发酵制备获得的发酵膜。常规工艺是在25-35℃的条件下,静态发酵3-7天制备获得。刚发酵完成的细菌纤维素膜吸收了大量剩余的发酵液、微生物代谢产物和微生物菌体,因此要经过一定处理才能用于伤口敷料。本领域技术人员可进一步对其进行改性,包括但不限于烷基化、羧甲基化、硝基化、氨基化、氨基甲酸酯等接枝或交联反应。
进一步地,在浸渍活性溶液之前,需要对细菌纤维素膜进行预处理,包括去除杂质、酸洗、碱洗、脱色等工艺,否则制备获得的纤维素膜颜色发黄,散发异味,且带有大量致热源,不利于作为伤口敷料的载体。
具体地说,所述细菌纤维素膜的处理依次包括:
浸入使用pH为10-12的氢氧化钠溶液,处理6-18小时;
浸入使用pH为7.5-10的次氯酸钠溶液,处理3-12小时;
浸入使用pH为2-4的草酸溶液处理,处理2-12小时。
其中,所述细菌纤维素膜的各个酸处理或碱处理工序中均使用15-30倍的酸液或碱液浸泡。
利用前述方法获得的细菌纤维素敷料,将敷料取出,挤压掉多余的水分,分切、分装、辐照灭菌,即获得成品。成品的外观呈白色半透明状,无杂质或黑点。膜片持液量不低于95%,细菌内毒素含量不超过1EU/cm2。
尽管细菌纤维素具有一定的吸附作用,可以吸附液体中游离的金属离子,有利于过氧化氢的稳定保存。但是低纯度过氧化氢水溶液在贮存过程中依然会发生缓慢的分解,因此需在配方体系中额外地加入过氧化氢稳定剂,以减缓过氧化氢的分解。
本发明制备获得的细菌纤维素敷料为湿性敷料产品,不仅可以轻松的贴敷于创面,而且贴敷料于创面可长达7天。在50℃加热25天,过氧化氢浓度降低率不超过15%。经20-40kGy辐照灭菌后过氧化氢浓度降低率不超过25%。
具体实施方式
下面结合具体实施例对本发明进行进一步说明。在未经特别说明的情况下,百分比均为质量百分比浓度。
实施例1
使用实验室的木醋杆菌菌种(Acetobacter Xylinum),接种到斜面固体培养基上培养菌落,然后进行种子培养,再在30℃恒温静态培养7天,用镊子取出细菌纤维素膜,清洗,干燥备用。
用工具刮掉细菌纤维素膜表面杂质,然后加入膜片质量20倍的纯化水中,超声波清洗20分钟。先使用0.5%浓度的氢氧化钠进行脱脂处理,料液比1:20,温度40-50℃,处理时间10小时。再使用10%次氯酸钠进行氧化漂白处理,料液比1:20,常温处理,处理时间6小时。再使用1%草酸溶液进行还原漂白处理,料液比1:20,常规处理,处理时间6小时。然后将膜片加入纯化水漂洗5遍。
配制活性溶液:
过氧化氢 0.4%,
PHMB 0.0002%,
乙二胺四乙酸二钠 0.01%。
将上述处理后的细菌纤维素膜加入等重量的活性溶液中浸泡,一段时间后取出,挤压多余水分,分切,灭菌,包装。
实施例2
本实施例采用与实施例1相同的方法制备,其区别在于活性溶液的配方如下:
过氧化氢 1%,
葡萄糖酸氯己定 0.06%,
酒石酸 0.03%。
实施例3
本实施例采用与实施例1相同的方法制备,其区别在于活性溶液的配方如下:
实施例4
本实施例采用与实施例1相同的方法制备,其区别在于活性溶液的配方如下:
过氧化氢 0.8%,
PHMB 0.0001%,
磷酸钠 0.2%。
实施例5
本实施例采用与实施例1相同的方法制备,其区别在于活性溶液的配方如下:
过氧化氢 1%,
PHMB 0.05%,
酒石酸 0.1%。
实施例6
本实施例采用与实施例1相同的方法制备,其区别在于活性溶液的配方如下:
过氧化氢 0.01%,
PHMB 0.0002%,
苹果酸 0.005%。
实施例7
本实施例采用与实施例1相同的方法制备,其区别在于活性溶液的配方如下:
过氧化氢 0.4%,
PHMB 0.0002%。
实施例8
本实施例采用与实施例1相同的方法制备,其区别在于活性溶液的配方如下:
过氧化氢 1%,
葡萄糖酸氯己定 0.06%。
实施例9
本实施例采用与实施例1相同的方法制备,其区别在于活性溶液的配方如下:
过氧化氢 0.6%,
尼泊金甲酯 0.02%,
尼铂金乙酯 0.05%。
试验例1
将实施例1-9获取的样品放置于50℃的烘箱中,分别于第0天、5天、10天、15天、20天、25天取样测试样品中过氧化氢的浓度。观察过氧化氢浓度的变化趋势。
具体操作:打开样品包装,用力挤出样品中的液体,收集于玻璃烧杯中。使用高锰酸钾滴定法检测试样过氧化氢含量。检测结果如表1所示:
表1高温老化对过氧化氢分解速度的影响
结论:上述试验表明,本发明提供的基于细菌纤维素薄膜负载过氧化氢及其稳定剂的技术方案能达到50℃加热25天过氧化氢浓度降低率(或分解速度)不超过15%的效果,氧化氢稳定剂浓度的降低会导致上述分解速度的增加,当浓度低于0.01%时,分解速度会超过50%。其中以EDTA-Na作为稳定剂的效果最好,特别是与尼泊金酯类杀菌剂的结合,可大幅降低过氧化氢分解速率;除此之外,酒石酸与胍类杀菌剂的配合也可有效降低分解速率。相对于实施例1-6,实施例7-9由于未加入过氧化氢稳定剂,无论是尼泊金酯类、有机酸类还是胍类消毒剂,5天后的分解速率已经超过15%,25天后的分解速率达到70%以上。
试验例2
将实施例1-9获取的样品分别测试辐照灭菌前后的过氧化氢浓度,辐照剂量为20-40kGy。
对于辐照或未经辐照的样品,用力挤出样品中的液体,收集于玻璃烧杯中。使用高锰酸钾滴定法检测试样过氧化氢含量。结果如表2所示:
表2辐照灭菌前后过氧化氢分解速度
上述数据表明,含有过氧化氢稳定剂可显著降低辐照对过氧化氢分解的影响。过氧化氢稳定剂浓度对辐照灭菌后样品中过氧化氢分解速度无显著影响。
试验例3
本试验基于实施例1-3和实施例7-9进行抑菌防腐试验。取样品挤出液,分别加入菌落浓度为105-106CFU/ml的细菌和真菌,参照防腐效能评价的方法,分别在第1天、第7天、第14天、第28天测试微生物的菌落总数,结果如表3和表4所示:
表3试样对金黄色葡萄球菌的抑制作用
表4试样对白色念珠菌的抑制作用
以上试验可以看出,本发明所述的过氧化氢稳定剂也具有一定的抑菌增效作用,其中以乙二胺四乙酸二钠和酒石酸对抑菌的增效作用最为显著。
以上所述仅是本发明的优选实施方式,应当指出:对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (9)
1. 一种负载活性氧的细菌纤维素敷料制备方法,其特征在于包括如下步骤:分别使用酸性溶液和碱性溶液处理细菌纤维素膜,漂洗;然后浸入活性溶液中,取出,挤压多余水分,分切,经20-40kGy辐照灭菌后包装,辐照灭菌后过氧化氢浓度降低率不超过25%;
其中,所述活性溶液包括过氧化氢、尼泊金酯类消毒剂和乙二胺四乙酸二钠,或
所述活性溶液包括过氧化氢、PHMB和酒石酸;
所述过氧化氢的浓度为0.05-1 wt%。
2. 根据权利要求1所述的方法,其特征在于:所述乙二胺四乙酸二钠或所述酒石酸的浓度为0.001-0.5 wt%。
3.根据权利要求1所述的方法,其特征在于:所述尼泊金酯类消毒剂或PHMB的浓度为0.5-5000ppm。
4.根据权利要求1所述的方法,其特征在于:所述细菌纤维素膜为利用木醋杆菌经静态培养发酵制备获得的发酵膜。
5.根据权利要求1所述的方法,其特征在于:所述细菌纤维素膜的处理依次包括:
浸入使用pH为10-12的氢氧化钠溶液,处理6-18小时;
浸入使用pH为7.5-10的次氯酸钠溶液,处理3-12小时;
浸入使用pH为2-4的草酸溶液处理,处理2-12小时。
6.根据权利要求5所述的方法,其特征在于:所述细菌纤维素膜的各个酸处理或碱处理工序中均使用15-30倍的酸液或碱液浸泡。
7.如权利要求1-6任意一项所述的制备方法获得的细菌纤维素敷料,其特征在于:所述敷料的外观呈白色半透明状,无杂质或黑点;膜片持液量不低于95%,细菌内毒素含量不超过1EU/cm2。
8.根据权利要求7所述的细菌纤维素敷料,其特征在于:在50℃加热25天,过氧化氢浓度降低率不超过15%。
9.根据权利要求8所述的细菌纤维素敷料,其特征在于:经20-40kGy辐照灭菌后过氧化氢浓度降低率不超过25%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211349098.2A CN115487340B (zh) | 2022-10-31 | 2022-10-31 | 一种负载活性氧的细菌纤维素敷料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211349098.2A CN115487340B (zh) | 2022-10-31 | 2022-10-31 | 一种负载活性氧的细菌纤维素敷料及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115487340A CN115487340A (zh) | 2022-12-20 |
CN115487340B true CN115487340B (zh) | 2023-11-17 |
Family
ID=85114722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211349098.2A Active CN115487340B (zh) | 2022-10-31 | 2022-10-31 | 一种负载活性氧的细菌纤维素敷料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115487340B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113607903B (zh) * | 2021-07-30 | 2024-03-15 | 振德医疗用品股份有限公司 | 一种检测含有正电荷聚合物细菌内毒素的方法 |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1301490A (zh) * | 1999-12-24 | 2001-07-04 | 董志建 | 杀菌消毒剂及其制备方法 |
CN1327367A (zh) * | 1998-10-19 | 2001-12-19 | 更家株式会社 | 杀菌/消毒过乙酸组合物 |
WO2004064880A1 (en) * | 2003-01-16 | 2004-08-05 | Xylos Corporation | Microbial-derived cellulose amorphous hydrogel wound dressing |
CN1552211A (zh) * | 2003-05-27 | 2004-12-08 | 拉萨绿能科技实业有限公司 | 提高过氧化氢杀菌活性的消毒剂及其制备工艺 |
CN101023753A (zh) * | 2006-02-21 | 2007-08-29 | 上海威理消毒剂有限公司 | 氧化型消毒灭菌剂及其制备方法 |
CN101392246A (zh) * | 2008-10-29 | 2009-03-25 | 东北电力大学 | 一种利用细菌纤维素膜做载体固定化白腐真菌的方法 |
CN101874043A (zh) * | 2007-11-26 | 2010-10-27 | 国立大学法人东京大学 | 纤维素纳米纤维及其制造方法、纤维素纳米纤维分散液 |
CN102058897A (zh) * | 2010-01-15 | 2011-05-18 | 东华大学 | 用于急性创伤的细菌纤维素基抗菌干膜及其制备方法和应用 |
CN102300587A (zh) * | 2008-11-07 | 2011-12-28 | 克洛克斯科技公司 | 用于伤口愈合的氧化剂和光活化剂的组合物 |
CN102625686A (zh) * | 2009-09-02 | 2012-08-01 | 希普罗特克有限公司 | 抗微生物医用敷料以及对伤口和导管部位的保护 |
CN103797182A (zh) * | 2011-09-12 | 2014-05-14 | 郡是株式会社 | 亲水化纤维素纤维的制造方法 |
CN103843817A (zh) * | 2012-12-06 | 2014-06-11 | 夏美洲 | 一种过氧化氢和过氧乙酸混合型消毒剂及其配制方法 |
CN106178066A (zh) * | 2015-05-07 | 2016-12-07 | 中国科学院化学研究所 | 一种改性纤维素/壳聚糖复合止血材料及其制备方法与应用 |
CN106689198A (zh) * | 2017-01-03 | 2017-05-24 | 中国人民解放军北京军区疾病预防控制中心 | 一种复方过氧化氢消毒剂及其制备方法和应用 |
EP3181153A1 (en) * | 2015-12-18 | 2017-06-21 | BSN medical GmbH | Wound care product comprising ecm-functionalized nanocellulose |
CN110225735A (zh) * | 2017-01-25 | 2019-09-10 | 墨尼克医疗用品有限公司 | 用于伤口处理的具有改善性能的纤维材料 |
CN110251728A (zh) * | 2019-07-01 | 2019-09-20 | 北京诺康达医药科技股份有限公司 | 一种生物外科补片的制备方法及基于该方法制备的生物外科补片 |
CN111264555A (zh) * | 2020-03-06 | 2020-06-12 | 吉林云飞医药有限公司 | 一种过氧化氢消毒液及其制备方法和应用 |
CN113575610A (zh) * | 2021-08-25 | 2021-11-02 | 四川恒通动保生物科技有限公司 | 一种耐低温过氧化氢消毒液及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090209897A1 (en) * | 2008-02-20 | 2009-08-20 | Lotec, Inc. Dba Vesta Sciences, Inc. | Photoactivated Antimicrobial Wound Dressing and Method Relating Thereto |
-
2022
- 2022-10-31 CN CN202211349098.2A patent/CN115487340B/zh active Active
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1327367A (zh) * | 1998-10-19 | 2001-12-19 | 更家株式会社 | 杀菌/消毒过乙酸组合物 |
CN1301490A (zh) * | 1999-12-24 | 2001-07-04 | 董志建 | 杀菌消毒剂及其制备方法 |
WO2004064880A1 (en) * | 2003-01-16 | 2004-08-05 | Xylos Corporation | Microbial-derived cellulose amorphous hydrogel wound dressing |
CN1552211A (zh) * | 2003-05-27 | 2004-12-08 | 拉萨绿能科技实业有限公司 | 提高过氧化氢杀菌活性的消毒剂及其制备工艺 |
CN101023753A (zh) * | 2006-02-21 | 2007-08-29 | 上海威理消毒剂有限公司 | 氧化型消毒灭菌剂及其制备方法 |
CN101874043A (zh) * | 2007-11-26 | 2010-10-27 | 国立大学法人东京大学 | 纤维素纳米纤维及其制造方法、纤维素纳米纤维分散液 |
CN101392246A (zh) * | 2008-10-29 | 2009-03-25 | 东北电力大学 | 一种利用细菌纤维素膜做载体固定化白腐真菌的方法 |
CN102300587A (zh) * | 2008-11-07 | 2011-12-28 | 克洛克斯科技公司 | 用于伤口愈合的氧化剂和光活化剂的组合物 |
CN102625686A (zh) * | 2009-09-02 | 2012-08-01 | 希普罗特克有限公司 | 抗微生物医用敷料以及对伤口和导管部位的保护 |
CN102091346A (zh) * | 2010-01-15 | 2011-06-15 | 东华大学 | 用于急性创伤的细菌纤维素基抗菌干膜及其制备和应用 |
CN102058897A (zh) * | 2010-01-15 | 2011-05-18 | 东华大学 | 用于急性创伤的细菌纤维素基抗菌干膜及其制备方法和应用 |
CN103797182A (zh) * | 2011-09-12 | 2014-05-14 | 郡是株式会社 | 亲水化纤维素纤维的制造方法 |
CN103843817A (zh) * | 2012-12-06 | 2014-06-11 | 夏美洲 | 一种过氧化氢和过氧乙酸混合型消毒剂及其配制方法 |
CN106178066A (zh) * | 2015-05-07 | 2016-12-07 | 中国科学院化学研究所 | 一种改性纤维素/壳聚糖复合止血材料及其制备方法与应用 |
EP3181153A1 (en) * | 2015-12-18 | 2017-06-21 | BSN medical GmbH | Wound care product comprising ecm-functionalized nanocellulose |
CN106689198A (zh) * | 2017-01-03 | 2017-05-24 | 中国人民解放军北京军区疾病预防控制中心 | 一种复方过氧化氢消毒剂及其制备方法和应用 |
CN110225735A (zh) * | 2017-01-25 | 2019-09-10 | 墨尼克医疗用品有限公司 | 用于伤口处理的具有改善性能的纤维材料 |
CN110251728A (zh) * | 2019-07-01 | 2019-09-20 | 北京诺康达医药科技股份有限公司 | 一种生物外科补片的制备方法及基于该方法制备的生物外科补片 |
CN111264555A (zh) * | 2020-03-06 | 2020-06-12 | 吉林云飞医药有限公司 | 一种过氧化氢消毒液及其制备方法和应用 |
CN113575610A (zh) * | 2021-08-25 | 2021-11-02 | 四川恒通动保生物科技有限公司 | 一种耐低温过氧化氢消毒液及其制备方法 |
Non-Patent Citations (2)
Title |
---|
Physical properties of bacterial cellulose composites for wound dressings;Wen-Shuo Chang et al;Food Hydrocolloids;75-83 * |
董永春主编.《纺织助剂化学》.东华大学出版社,2010,第154-155页. * |
Also Published As
Publication number | Publication date |
---|---|
CN115487340A (zh) | 2022-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5326567A (en) | Antimicrobial compositions useful for medical applications | |
US5607683A (en) | Antimicrobial compositions useful for medical applications | |
CN115487340B (zh) | 一种负载活性氧的细菌纤维素敷料及其制备方法 | |
JP7020700B2 (ja) | 抗菌組成物 | |
EP3669898B1 (en) | Hemostatic anti-infection wound dressing and preparation method thereof | |
FR2543440A1 (fr) | Procede de preparation d'un tissu animal a usage de pansement pour brulures et blessures et tissu obtenu par un tel procede | |
CN102159083A (zh) | 抗微生物组合物 | |
CN111939270A (zh) | 一种具有持续抗菌效果的双纳米酶抗菌剂及其制备方法 | |
CN105326853A (zh) | 一种复合壳聚糖材料及其制备方法和用途 | |
CN113144281B (zh) | 一种伤口创面消毒凝胶及其制备方法 | |
CN111184906B (zh) | 一种基于pva的液体敷料及其制备方法 | |
CA2692094C (en) | Antimicrobial compositions | |
KR20230060724A (ko) | 바이오 복합체 및 이의 제조방법 | |
US11554137B2 (en) | Composition and method for arresting blood flow and for forming a persistent microbial barrier | |
EP3990037B1 (en) | Layered collagen dressing with extended bacteria and biofilm reducing capabilities | |
CN114522268B (zh) | 一种皮肤修复材料及其制备方法和应用 | |
CN114957511A (zh) | 一种褐藻胶寡糖锌及其制备方法和应用 | |
CN111298108A (zh) | 一种儿童长效型复合酶消毒组合物及应用 | |
CN113521374A (zh) | 血管外科用纳米止血抗菌复合材料及其制备方法 | |
CN117814296A (zh) | 一种天然复合果蔬保鲜喷雾剂及其制备方法和应用 | |
CN111973629A (zh) | 一种伤口消毒冲洗液及其制备方法 | |
CN116421481A (zh) | 一种复配防腐剂及其制备方法 | |
TW201420609A (zh) | 除菌保護劑 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |